Affiliation:
1. GlaxoSmithKline Research and Development, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
Abstract
ABSTRACT
Genomic technologies have the potential to greatly increase the efficiency of the drug development process. As part of our tuberculosis drug discovery program, we used DNA microarray technology to profile drug-induced effects in
Mycobacterium tuberculosis
. Expression profiles of
M. tuberculosis
treated with compounds that inhibit key metabolic pathways are required as references for the assessment of novel antimycobacterial agents. We have studied the response of
M. tuberculosis
to treatment with the mycolic acid biosynthesis inhibitors isoniazid, thiolactomycin, and triclosan. Thiolactomycin targets the β-ketoacyl-acyl carrier protein (ACP) synthases KasA and KasB, while triclosan inhibits the enoyl-ACP reductase InhA. However, controversy surrounds the precise mode of action of isoniazid, with both InhA and KasA having been proposed as the primary target. We have shown that although the global response profiles of isoniazid and thiolactomycin are more closely related to each other than to that of triclosan, there are differences that distinguish the mode of action of these two drugs. In addition, we have identified two groups of genes, possibly forming efflux and detoxification systems, through which
M. tuberculosis
may limit the effects of triclosan. We have developed a mathematical model, based on the expression of 21 genes, which is able to perfectly discriminate between isoniazid-, thiolactomycin-, or triclosan-treated
M. tuberculosis
. This model is likely to prove invaluable as a tool to improve the efficiency of our drug development programs by providing a means to rapidly confirm the mode of action of thiolactomycin analogues or novel InhA inhibitors as well as helping to translate enzyme activity into whole-cell activity.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference33 articles.
1. Alland, D., I. Kramnik, T. R. Weisbrod, L. Otsubo, R. Cerny, L. P. J. W. Miller, and B. R. Bloom. 1998. Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL)—the effect of isoniazid on gene expression in Mycobacterium tuberculosis.Proc. Natl. Acad. Sci. USA95:13227-13232.
2. Genome-Wide Expression Patterns in
Saccharomyces cerevisiae
: Comparison of Drug Treatments and Genetic Alterations Affecting Biosynthesis of Ergosterol
3. Banerjee, A., E. Dubnau, A. Quemard, A. S. Balasubramanian, K. S. Um, T. Wilson, D. Collins, G. W. de Lisle, and W. R. Jacobs. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.Science263:227-230.
4. Barry, C. E., M. Wilson, R. Lee, and G. K. Schoolnik. 2000. DNA microarrays and combinatorial chemical libraries: tools for the drug discovery pipeline. Int. J. Tuberc. Lung Dis.4:S189-S193.
5. Betts, J. C. 2002. Transcriptomics and proteomics: tools for the identification of novel drug targets and vaccine candidates for tuberculosis. IUBMB Life53:239-242.
Cited by
125 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献